The World Health Organization (WHO) has released a significant new guideline on the use of non-sugar sweeteners (NSS), often colloquially known as artificial or low-calorie sweeteners. The organization’s comprehensive review of existing scientific literature has led to a strong recommendation against the use of NSS for controlling body weight or reducing the risk of noncommunicable diseases. This guidance, published in mid-2023, marks a notable shift in the global health discourse surrounding these widely consumed food additives.
WHO’s Core Recommendation and Rationale
At the heart of the WHO’s advisory is the conclusion that replacing sugar with NSS does not offer a long-term advantage for weight management in either adults or children. While acknowledging that some short-term clinical trials indicated a reduction in calorie intake when NSS replaced sugar in food and beverages, the WHO emphasized the lack of sustained weight loss benefits over extended periods. Furthermore, the review found no consistent or significant impact of NSS on levels of hunger or satiety. Some studies reported a decrease in hunger, while others observed an increased appetite among participants consuming higher quantities of NSS-containing products, highlighting the variability and complexity of NSS’s effects on appetite regulation.
Observational Data and Disease Risk
Beyond weight management, the WHO’s guideline delved into the potential associations between NSS consumption and chronic diseases. Analysis of observational cohort studies revealed a concerning link between the long-term intake of NSS-containing beverages and an elevated risk of cardiovascular disease and premature death in adults. Similarly, higher consumption of NSS, whether added to foods or beverages, was associated with an increased likelihood of developing type 2 diabetes.
The organization, however, was careful to note the potential for "reverse causation" in these observational findings. This phenomenon suggests that individuals already at higher risk for chronic diseases, such as those with a higher body mass index (BMI) or existing metabolic risk factors, might be more inclined to choose NSS as a perceived healthier alternative to sugar. This pre-existing predisposition to illness could therefore explain the observed positive association between NSS use and disease risk, rather than NSS directly causing the diseases. Importantly, the WHO’s review did not find a significant association between NSS consumption and an increased risk of cancer or cancer-related mortality.
The Nutritional Void and Early Intervention
Based on its comprehensive analysis, the WHO strongly advises a dietary shift towards reducing the overall sweetness in one’s diet, advocating for this change to begin early in life. The rationale is rooted in the fact that NSS provide no nutritional value. The guideline specifically names common NSS such as acesulfame K, aspartame, saccharin, sucralose, and stevia. It is important to note that the WHO’s analysis did not encompass sugar alcohols, also known as polyols, such as maltitol, xylitol, and sorbitol, which are frequently found in a variety of foods and beverages.
Expert Commentary and Points of Contention
The WHO’s guidance has garnered attention and discussion within the scientific community. Experts from the Harvard T.H. Chan School of Public Health, while generally concurring with the recommendation to moderate sugar intake, have raised specific criticisms regarding the WHO’s meta-analysis. Notably, they pointed out the exclusion of certain large-scale cohort studies. These omitted studies, which collectively involved over 100,000 participants, had previously indicated that substituting sugar-sweetened beverages with artificially sweetened alternatives was associated with reduced weight gain over time. This finding aligns with the results of smaller, short-term randomized controlled trials.
Statistical modeling based on these excluded studies suggested that replacing one serving of a sugar-sweetened beverage with an artificially sweetened one could be associated with a 4% lower risk of total mortality, a 5% lower risk of cardiovascular disease-related mortality, and a 4% lower risk of cancer-related mortality. This highlights a divergence in interpretation and the impact of study selection on the final conclusions.
Prioritizing Optimal Beverage Choices
Frank Hu, Chair of the Department of Nutrition at the Harvard T.H. Chan School of Public Health, offered a nuanced perspective on beverage consumption. He stated that for individuals who habitually consume sugar-sweetened beverages, artificially sweetened drinks could serve as a temporary transitional option. However, he underscored that the most beneficial choices for long-term health remain water and unsweetened coffee or tea. This emphasizes a hierarchy of beverage choices, with NSS occupying a secondary, potentially transitional role rather than a primary healthy alternative.
Broader Context: The Aspartame Debate
The WHO’s broader guidance on NSS arrives amidst ongoing scrutiny of specific sweeteners. In July 2023, the International Agency for Research on Cancer (IARC), a branch of the WHO, and the Joint FAO/WHO Expert Committee on Food Additives (JECFA) released a risk assessment of aspartame. The IARC classified aspartame as a Group 2B carcinogen, indicating "limited evidence" of carcinogenicity in humans, specifically concerning liver cancer.
Despite this classification, JECFA maintained its previously established acceptable daily intake (ADI) for aspartame at 40 mg per kilogram of body weight. They affirmed that their research review did not provide evidence to alter this guideline, concluding that intake within this range is safe. For an average 150-pound (68 kg) woman, this ADI translates to a limit of approximately 2,727 mg of aspartame per day, roughly equivalent to eleven 12-ounce cans of diet soda, with each can typically containing around 250 mg of aspartame. The committee acknowledged that the evidence on cancer risk from both animal and human studies was not yet convincing and that further research, including longer-term studies and randomized controlled trials, is warranted. This dual assessment from WHO entities underscores the complexity of evaluating food additives, with different bodies focusing on hazard identification versus risk assessment.
Implications for Public Health and Consumer Choices
The WHO’s guideline has significant implications for public health recommendations, food labeling, and consumer behavior. It challenges the long-held assumption that NSS are a universally beneficial tool for weight management and disease prevention. The emphasis on reducing overall sweetness in the diet, particularly from an early age, suggests a need for broader public health campaigns focused on dietary habits and taste preferences.
For consumers, the guidance prompts a re-evaluation of their beverage and food choices. While NSS may offer a way to reduce sugar intake in the short term, the WHO’s findings suggest that they are not a sustainable solution for improving long-term health outcomes. The debate also highlights the importance of understanding the nuances of scientific research, including the differences between observational studies and randomized controlled trials, and the potential for biases like reverse causation.
The continued scientific investigation into specific sweeteners like aspartame also indicates that the landscape of food additive safety is dynamic. As research evolves, public health guidance may be subject to revision, underscoring the importance of staying informed and consulting with healthcare professionals for personalized dietary advice. The WHO’s latest guideline serves as a critical piece of evidence in this ongoing conversation, steering the focus towards a more holistic approach to diet and health.
